- Home
- SLNO vs BEAM Comparison
SLNO vs BEAM Comparison
Compare SLNO & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLNO
- BEAM
- Stock Information
- Founded
- SLNO 1999
- BEAM 2017
- Country
- SLNO United States
- BEAM United States
- Employees
- SLNO N/A
- BEAM N/A
- Industry
- SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SLNO Health Care
- BEAM Health Care
- Exchange
- SLNO Nasdaq
- BEAM Nasdaq
- Market Cap
- SLNO 3.8B
- BEAM 1.9B
- IPO Year
- SLNO 2014
- BEAM 2020
- Fundamental
- Price
- SLNO $83.47
- BEAM $19.45
- Analyst Decision
- SLNO Strong Buy
- BEAM Strong Buy
- Analyst Count
- SLNO 9
- BEAM 11
- Target Price
- SLNO $105.11
- BEAM $48.90
- AVG Volume (30 Days)
- SLNO 1.5M
- BEAM 2.4M
- Earning Date
- SLNO 08-06-2025
- BEAM 08-05-2025
- Dividend Yield
- SLNO N/A
- BEAM N/A
- EPS Growth
- SLNO N/A
- BEAM N/A
- EPS
- SLNO N/A
- BEAM N/A
- Revenue
- SLNO N/A
- BEAM $63,578,000.00
- Revenue This Year
- SLNO N/A
- BEAM N/A
- Revenue Next Year
- SLNO N/A
- BEAM $17.18
- P/E Ratio
- SLNO N/A
- BEAM N/A
- Revenue Growth
- SLNO N/A
- BEAM N/A
- 52 Week Low
- SLNO $41.50
- BEAM $13.53
- 52 Week High
- SLNO $90.32
- BEAM $35.25
- Technical
- Relative Strength Index (RSI)
- SLNO 51.94
- BEAM 63.94
- Support Level
- SLNO $79.70
- BEAM $20.75
- Resistance Level
- SLNO $90.32
- BEAM $22.51
- Average True Range (ATR)
- SLNO 3.45
- BEAM 1.18
- MACD
- SLNO -0.57
- BEAM 0.35
- Stochastic Oscillator
- SLNO 26.46
- BEAM 74.58
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.